Teijin Pharma Limited.
https://www.teijin-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Teijin Pharma Limited.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
Japan Drug Price Revision: Cuts, Increases Aim To Balance National Healthcare Costs
Japan will raise reimbursement prices for selected essential and clinically valuable drugs in April, while cutting back prices for a higher than usual number of other products through the broad application of market expansion repricing rules. The overall regular revision will see prices cut by 4.7% on average.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Rehabilitation Equipment and Devices
- Other Names / Subsidiaries
-
- MedTech Heart
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice